Home Our statement on the British SARS-CoV-2 variant with multiple spike protein mutations

Our statement on the British SARS-CoV-2 variant with multiple spike protein mutations

Manufacturer:	GENERI BIOTECH s.r.o.
	Machkova 587/42, 500 11 Hradec Králové 11 – Třebeš, Czech Republic

hereby declares, that the SARS-CoV-2 virus detection with the use of the following real-time PCR diagnostic kits as the In vitro diagnostic medical devices (IVD) listed below:

gb Sarbeco E (primary test)	Cat. no. 3227-500 a 3227-100
gb SARS-CoV-2 RdRP (confirmation test)	Cat. no. 3228-500 a 3228-100
gb Sarbeco N (primary test)	Cat. no. 3229-500 a 3229-100
gb SARS-CoV-2 N (confirmation test)	Cat. no. 3230-500 a 3230-100
gb SARS-CoV-2 Multiplex	Cat. no. 3231-500, 3231-200 a 3231-050
gb SARS-CoV-2 Combi	Cat. no. 3232-500 a 3232-100
gb SARS-CoV-2 Influenza A/B	Cat. no. 3233-500 a 3233-100
gb SARS-CoV-2 Multiplex EndoC	Cat. no. 3234-M, 3234-500 a 3234-100
gb SARS-CoV-2 Combi EndoC	Cat. no. 3235-M, 3235-500 a 3235-100

is not affected by any of the mutations – deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H or other newly described mutations in the S gene encoding the Spike protein of the SARS-CoV-2 virus.

Our systems are designed in accordance with WHO protocols based on recommendations of laboratories of Charité (region of E gene), Institut Pasteur (region of RdRP gene) and CDC (region of N gene). These regions are considered very conservative and we regularly check this fact by in silico analysis of SARS-CoV-2 sequences in the GISAID and NCBI databases. Mutations that are monitored for accelerated spread of SARS-CoV-2 virus occur primarily in the S gene for Spike protein, and therefore do not affect any of the performance parameters (detection sensitivity or specificity) of our IVD kits.